Navigation Links
AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test

Company now officially following an FDA 510(k) (Pre-Market Notification) Pathway for AppyScore(TM), the First Blood-based Screening and Triage Test

for Human Appendicitis

CASTLE ROCK, Colo., Nov. 27 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has received an official response from the Food and Drug Administration (FDA) Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) regarding AspenBio's pre-investigational device exemption ("IDE") application on AppyScore(TM), the first blood-based screening/triage test for human appendicitis.

The official response from FDA has provided the company with the choice of pursuing either an FDA 510(k) (Pre-Market Notification) regulatory clearance or a PMA (Pre-Market Approval) for AppyScore. Based on this response, the company has now officially chosen to follow the 510(k) pathway. Generally the FDA's 510(k) application pathway has a much shorter time-line to clearance than the alternative PMA process. The company expects to complete the appropriate regulatory requirements to receive a 510(k) clearance for AppyScore before the end of 2008.

"This represents another major milestone in the advancement of our breakthrough screen test for appendicitis," said AspenBio's president and CEO, Richard Donnelly, "and demonstrates the strength of our initial clinical results and particularly the high sensitivity of AppyScore. We expect the FDA 510(k) to be a faster and easier path for regulatory clearance and market launch of this product. Most importantly, it creates the possibility of being able to begin marketing the first version of this test in the United States and certain international markets in 2008."

About AppyScore and the Need for a New Method of Diagnosing Appendicitis

AspenBio's AppyScore is the first blood-based Screen/Triage Test for human appendicitis. An estimated 5% to 7% of the world's population will get appendicitis in their lifetime. Annually, in the U.S. alone, an estimated 6 million patients enter hospital emergency rooms (ERs) complaining of abdominal pain, and who could potentially have appendicitis. Upon entering the ER, the current standard of care for these patients is to draw blood and urine samples, take vital signs and complete an initial physical health examination. Depending upon the results and clinical impression of the ER physician, a computed tomography (CT) scan may also be scheduled to assist in the diagnosis or rule out of appendicitis. CT scans generally take several hours to schedule and complete the procedure, and interpret the results. Moreover, CT scans are expensive, costing $1,500 to $3,000 each, and subject patients (mostly children and adolescents) to high levels of ionizing radiation.

Based upon the current standard of care, an estimated 700,000 patients in the U.S. are diagnosed with appendicitis and have their appendixes surgically removed. However, an estimated 1 in 5 to 1 in 7 (14% to 20%) appendectomy surgeries remove a normal appendix due to an incorrect diagnosis. This would mean more than a 100,000 unnecessary surgeries occur every year at a great cost to patients, insurance companies and create unnecessary pain, suffering and risk to human life and possibly other ongoing patient health issues.

Not properly detecting real cases of appendicitis is also a major problem. A large independent research report (Graff et al., 2000 Acad Emerg Med Vol 7 n 11 pp 1244-55) of approximately 1,026 appendicitis patients from 12 hospitals across the northeastern United States reported that an average of 18.6% of patients (ranging from 10.6% to 27.8% per hospital) were incorrectly diagnosed as not having appendicitis and were sent home, only to return to the emergency room with acute appendicitis in an advanced or burst condition. If the Graff report is representative of the state-of-the-art diagnostics for appendicitis, then the 98% sensitivity level of AppyScore -- as reported by company's recent large-scale multi-hospital study -- demonstrates the substantial impact this screening test could have for life threatening misdiagnoses. The false negative diagnosis of appendicitis could become much less frequent using AppyScore, resulting in fewer patients with appendicitis being erroneously sent home.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, please visit:

Forward Looking Statements

This news release includes "forward looking statements" of AspenBio Pharma, Inc. ("APPY") as defined by the Securities and Exchange Commission (the "SEC"). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APPY believes or anticipates will or may occur in the future are forward- looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APPY believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APPY. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including the ability to successfully complete the development of, obtain FDA clearance for and generate revenues from the appendicitis test and other new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, obtain and enforce intellectual property rights, and realization of intangible assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APPY's recent filings with the SEC.

For more information contact:

AspenBio Pharma, Inc.

Gregory Pusey, Chairman

Tel 303-722-4008

Investor Relations:

Liolios Group, Inc.

Scott Liolios or Ron Both

Tel 949-574-3860

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. AspenBio Pharma Reports Second Quarter 2007 Results
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
4. AspenBio Pharma to Present the Edgewater Research Investor Conference
5. AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/8/2015)... 2015 Global Biologics and ... and Biosimilars industry . --> Big ... Biosimilars Industry 2015 Deep Market Research Report, Size, ... professional and depth research report on Global ... ) , --> ) , ...
(Date:10/8/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, today announced its schedule of ... in the month of October: Stem Cell ... will be presenting at the annual Partnering Forum, part ... be held October 7-9 in La Jolla, ...
(Date:10/8/2015)... ... October 08, 2015 , ... ... an exclusive license agreement to develop and commercialize intellectual property rights belonging to ... agreement from February 2009, and affords exclusive worldwide rights to intellectual property based ...
(Date:10/7/2015)... ... October 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal ... October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is ... , He is the Co-Founder and Chief Science Officer of the ...
Breaking Biology Technology:
... Mach One Corporation (Pink Sheets: MNCN), a global ... long term benefit to the agricultural and consumer markets, ... of Modular Process Constructors LLC (MPC).Mach One acquired 100% ... Series B convertible preferred stock at a conversion price ...
... Accuray Incorporated,(Nasdaq: ARAY ), a ... today,that 10 percent of its U.S. installed base ... service. Treatment planning by medical physicists,is a core ... , Accuray,s treatment planning ...
... 20 Elsevier announced today,that Scopus(R), its ... (A&C) database, was chosen by the Australian ... for Australia (ERA) initiative. , ... research quality within Australia,s higher,education institutions using ...
Cached Biology Technology:
(Date:10/6/2015)... 2015  Maverix Biomics, Inc., a leading genomic ... software portfolio with the debut of its RNA-Seq ... in eukaryotes. The software is integrated into the ... analysis solution that leverages proven open-source algorithms and ... efforts. Garry Nolan,s laboratory at ...
(Date:10/2/2015)... -- ) has announced ... Using Biometrics" report to their offering. ... of the "Enforcing the Law Using Biometrics" ... Research and Markets ( ) has announced ... Using Biometrics" report to their offering. ...
(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
Breaking Biology News(10 mins):
... the University of Iowa and Brigham Young University (BYU) ... for overcoming drug resistance in cancer. The finding could ... cancer and monitoring patients, response to treatment but also ... cancer cells. Drug resistance is a common problem ...
... new open access publishing program that offers immediate publication ... process, executed after publication. Following recent approval by the ... that pass this peer review process will now be ... F1000Research ,s acceptance by the NLM ...
... register now for the American College of Medical Genetics ... 2013 at the Phoenix Convention Center. From Genetic Testing ... Meeting is on the actual practice of genetics and ... conference will showcase the latest breakthroughs in genetics research ...
Cached Biology News:
... MW: 60kDa (A) and 36kDa (C) ... pH 7.5, 500mM NaCl, 60mM 2-mercaptoethanol, ... 1mM DTT, and 0.1mg/ml serum albumin ... of proteins. Purification: DEAE chromatography, aminohexyl-agarose ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
... This kit allows for quick and reproducible ... plate. The system is more reproducible than regular ... the protein A/G agarose without disrupting the agarose ... Catch and Release is reversible, and elution of ...
Biology Products: